Maddi Hebebrand

4 weeks ago | dermatologytimes.com | Emma Andrus |Maddi Hebebrand

Today, the US FDA approved dupilumab (Dupixent; Regeneron and Sanofi) for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who have not previously reached controlled disease status with H1 antihistamine treatment.1The approval marks the introduction of the first targeted therapy for CSU in more than a decade.

1 month ago | dermatologytimes.com | Kaitlyn Bader |Maddi Hebebrand

“We need new options. We need nonsteroidal options. We need to simplify the treatment regimen.... I think this is good news, not only for our young pediatric population but also our entire atopic dermatitis population,” Linda Stein Gold, MD, FAAD, said in an interview with Dermatology Times onsite at the 2025 American Academy of Dermatology Annual Meeting.

1 month ago | dermatologytimes.com | Emma Andrus |Maddi Hebebrand

PublicationArticleMarch 18, 2025Dermatology TimesDermatology Times, March 2025 (Vol. 46. No. 03)Volume46 Issue 03Author(s):,Join Dermatology Times in celebrating the women who make this field shine through their patient interactions, clinical insights, and research. As treatment guidelines, medical treatments, and patient perspectives change, so too has the demographic makeup of the dermatology specialty.

2 months ago | dermatologytimes.com | Emma Andrus |Maddi Hebebrand

The US FDA recently issued an alert regarding potential benzene contamination in benzoyl peroxide (BPO)-containing products.1 The agency conducted independent testing of 95 acne treatment products after receiving third-party reports raising concerns about elevated benzene levels. The FDA's findings indicate that more than 90% of the tested products had either undetectable or extremely low levels of benzene.

2 months ago | dermatologytimes.com | Maddi Hebebrand |Emma Andrus

Author(s):,Published in JID, the paper analyzes the FDA’s FAERS database and cases of neoplasms such as skin cancer, breast cancer, and other malignancies.